Grunberg Gregory 4
4 · Kala Pharmaceuticals, Inc. · Filed Jul 26, 2017
Insider Transaction Report
Form 4
Grunberg Gregory
Director10% Owner
Transactions
- Conversion
Common Stock
2017-07-25+2,055,946→ 2,055,946 total(indirect: By Longitude Venture Partners II, L.P.) - Conversion
Series C Preferred Stock
2017-07-25−10,707,985→ 0 total(indirect: By Longitude Venture Partners II, L.P.)→ Common Stock (2,055,946 underlying) - Purchase
Common Stock
2017-07-25$15.00/sh+215,000$3,225,000→ 2,270,946 total(indirect: By Longitude Venture Partners II, L.P.)
Footnotes (4)
- [F1]The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]These shares are held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F3]Includes 215,000 shares of Common Stock acquired by Longitude Venture Partners, II, L.P in the Issuer's initial public offering.
- [F4]These shares were held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.